EX-99.2 3 a2020q4exhibit992.htm EX-99.2 Document

Exhibit 99.2




Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)FOURTH QUARTER
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $11,809  10,774 9.6% 9.6  -
Europe 5,271  4,663 13.07.75.3
Western Hemisphere excluding U.S. 1,404  1,495  (6.1)2.9 (9.0)
Asia-Pacific, Africa 3,991  3,815 4.60.73.9
International 10,666  9,973 7.04.32.7
      
Worldwide $22,475  20,747 8.3% 7.1 1.2
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)TWELVE MONTHS
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $43,133  42,097 2.5 %2.5  -
Europe 18,980  18,466  2.8  2.0  0.8
Western Hemisphere excluding U.S. 5,335  5,941  (10.2) 0.4  (10.6)
Asia-Pacific, Africa 15,136  15,555  (2.7) (3.1) 0.4
International 39,451  39,962  (1.3) (0.2) (1.1)
      
Worldwide $82,584  82,059  0.6 % 1.2  (0.6)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.







Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)FOURTH QUARTER
 Percent Change
20202019TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$1,509 1,470 2.7 %2.7— 
    International2,109 2,097 0.5 1.5 (1.0)
3,618    3,567 1.4 2.0 (0.6)
Pharmaceutical
    U.S.7,116 6,169 15.3 15.3— 
    International5,152 4,379 17.7 13.54.2 
12,268    10,548 16.3 14.61.7 
Medical Devices
    U.S.3,184    3,135 1.5 1.5 — 
    International3,405 3,497 (2.6)(5.5)2.9 
 6,589    6,632 (0.7)(2.2)1.5 
U.S.11,809 10,774 9.6 9.6 — 
International10,666 9,973 7.0 4.3 2.7 
Worldwide$22,475 20,747 8.3 %7.1 1.2 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)TWELVE MONTHS
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$6,362  5,839  9.0 % 9.0  -
    International 7,691  8,059  (4.6) (1.3) (3.3)
 14,053     13,898  1.1  3.0  (1.9)
Pharmaceutical
    U.S. 25,735  23,874  7.8  7.8  -
    International 19,837  18,324  8.3  8.8  (0.5)
 45,572     42,198  8.0  8.2  (0.2)
Medical Devices
    U.S. 11,036     12,384  (10.9) (10.9) -
    International 11,923  13,579  (12.2) (11.8) (0.4)
  22,959     25,963  (11.6) (11.4) (0.2)
U.S. 43,133  42,097 2.5 2.5  -
International 39,451  39,962  (1.3) (0.2) (1.1)
Worldwide$82,584  82,059  0.6 % 1.2  (0.6)
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)FOURTH QUARTER
20202019Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$22,475 100.0$20,747 100.08.3 
Cost of products sold7,814 34.87,134 34.49.5 
Gross Profit14,661 65.213,613 65.67.7 
Selling, marketing and administrative expenses6,457 28.76,039 29.16.9 
Research and development expense4,032 17.93,232 15.624.8 
In-process research and development37 0.2 — — 
Interest (income) expense, net74 0.3 4 0.0 
Other (income) expense, net2,354 10.5 16 0.1 
Restructuring60 0.3104 0.5
Earnings before provision for taxes on income1,647 7.34,218 20.3(61.0)
Provision for/(Benefit from) taxes on income(91)(0.4)208 1.0 (143.8)
Net earnings$1,738 7.7$4,010 19.3(56.7)
Net earnings per share (Diluted)$0.65 $1.50 (56.7)
Average shares outstanding (Diluted)2,669.2 2,669.1 
Effective tax rate(5.5)%4.9 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$5,601 24.9$5,628 27.1(0.5)
Net earnings$4,965 22.1$5,027 24.2(1.2)
Net earnings per share (Diluted)$1.86 $1.88 (1.1)
Effective tax rate11.4 %10.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.








Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)TWELVE MONTHS
20202019Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$82,584 100.0 $82,059 100.0 0.6
Cost of products sold 28,427 34.4  27,556 33.6 3.2
Gross Profit 54,157 65.6  54,503 66.4 (0.6)
Selling, marketing and administrative expenses 22,084 26.8  22,178 27.0 (0.4)
Research and development expense 12,159 14.7  11,355 13.8 7.1
In-process research and development 181 0.2  890 1.1  
Interest (income) expense, net 90 0.1  (39)0.0  
Other (income) expense, net 2,899 3.5  2,525 3.1  
Restructuring 247 0.3  266 0.3
Earnings before provision for taxes on income 16,497 20.0  17,328 21.1 (4.8)
Provision for taxes on income 1,783 2.2  2,209 2.7 (19.3)
Net earnings$14,714 17.8 $15,119 18.4 (2.7)
Net earnings per share (Diluted)$5.51 $5.63 (2.1)
Average shares outstanding (Diluted)2,670.72,684.3
Effective tax rate10.8%12.7%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$25,428 30.8$28,225 34.4(9.9)
Net earnings$21,433 26.0$23,310 28.4(8.1)
Net earnings per share (Diluted)$8.03 $8.68 (7.5)
Effective tax rate15.7%17.4%
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.





Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Fourth Quarter
(Dollars in Millions Except Per Share Data)20202019
Net Earnings, after tax- as reported$1,738$4,010
Pre-tax Adjustments
Intangible Asset Amortization expense1,2341,142
Litigation expense, net2,902264
IPR&D37-
Restructuring related85251
Acquisition and Integration related1490
Unrealized (gains)/losses on securities(373)(350)
Medical Device Regulation 1
55-
Other-13
Tax Adjustments
Tax impact on special item adjustments 2
(606)(123)
Tax legislation and other tax related(121)(270)
Adjusted Net Earnings, after tax$4,965$5,027
Average shares outstanding (Diluted)2,669.22,669.1
Adjusted net earnings per share (Diluted)$1.86$1.88
Operational adjusted net earnings per share (Diluted)$1.82
Notes:
1
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
2
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
Prior year amounts have been reclassified to conform to current year disclosure





Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Twelve Months Ended
(Dollars in Millions Except Per Share Data)20202019
Net Earnings, after tax- as reported$14,714$15,119
Pre-tax Adjustments
Intangible Asset Amortization expense4,660 4,528
Litigation expense, net5,112 5,096
IPR&D 181 890
Restructuring related448 611
Acquisition and Integration related ¹(1,073)319
Unrealized (gains)/losses on securities(547)(567)
Medical Device Regulation 2
144  -
Other 6  20
Tax Adjustments
Tax impact on special item adjustments 3
(1,608)(1,977)
Tax legislation and other tax related(604)(729)
Adjusted Net Earnings, after tax$21,433$23,310
Average shares outstanding (Diluted)2,670.7 2,684.3
Adjusted net earnings per share (Diluted)$8.03$8.68
Operational adjusted net earnings per share (Diluted)$8.00 
Notes:
1
Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
3
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
Prior year amounts have been reclassified to conform to current year disclosure



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
Fourth Quarter 2020 Actual vs. 2019 Actual
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 1.4 %16.3 %(0.7)%8.3 %
 U.S. 2.7 %15.3 %1.5 %9.6 %
 International 0.5 %17.7 %(2.6)%7.0 %
 WW Currency (0.6)1.71.51.2
 U.S. ————
 International (1.0)4.22.92.7
 WW Operational 2.0 %14.6 %(2.2)%7.1 %
 U.S. 2.7 %15.3 %1.5 %9.6 %
 International 1.5 %13.5 %(5.5)%4.3 %
General Surgery
Advanced Sterilization Products0.60.2
 U.S. 0.00.0
 International 1.00.4
All Other Acquisitions and Divestitures0.10.00.10.1
 U.S. 0.1(0.1)0.20.0
 International 0.10.20.00.1
WW Adjusted Operational2.1 %14.6 %(1.5)%7.3 %
 U.S. 2.8 %15.2 %1.7 %9.6 %
 International 1.6 %13.7 %(4.4)%4.8 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.








Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
Twelve Months 2020 Actual vs. 2019 Actual
Segments
Consumer HealthPharmaceuticalMedical DevicesTotal
WW As Reported1.1 %8.0 %(11.6)%0.6 %
U.S.9.0 %7.8 %(10.9)%2.5 %
International(4.6)%8.3 %(12.2)%(1.3)%
WW Currency(1.9)(0.2)(0.2)(0.6)
U.S.————
International(3.3)(0.5)(0.4)(1.1)
WW Operational3.0 %8.2 %(11.4)%1.2 %
U.S.9.0 %7.8 %(10.9)%2.5 %
International(1.3)%8.8 %(11.8)%(0.2)%
Skin Health / Beauty
Dr. Ci Labo - Japan(0.1)0.0
U.S.0.00.0
International(0.2)0.0
General Surgery
Advanced Sterilization Products0.80.3
U.S.0.60.2
International1.00.4
Baby Care
Baby Center0.20.0
U.S.0.50.1
International0.00.0
All Other Acquisitions and Divestitures0.00.20.00.1
U.S.0.00.00.00.0
International(0.1)0.30.00.1
WW Adjusted Operational3.1 %8.4 %(10.5)%1.5 %
U.S.9.5 %7.8 %(10.2)%2.8 %
International(1.5)%9.1 %(10.9)%0.2 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.


Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20202019Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$5435420.1 %0.1 %— %
Intl642653(1.7)(2.9)1.2 
WW1,1851,195(0.8)(1.5)0.7 
SKIN HEALTH / BEAUTY (4)
US5835820.2 0.2 — 
Intl5945684.6 5.0 (0.4)
WW1,177 1,1502.4 2.6 (0.2)
ORAL CARE
US1731598.3 8.3 — 
Intl26423313.5 14.5 (1.0)
WW437 393 11.4 12.0 (0.6)
BABY CARE
US978514.3 14.3 — 
Intl310336(7.8)(3.6)(4.2)
WW407 421 (3.4)0.0 (3.4)
WOMEN'S HEALTH
US3311.8 11.8 — 
Intl234250(6.5)(3.1)(3.4)
WW237253(6.3)(2.9)(3.4)
WOUND CARE / OTHER
US1109811.8 11.8 — 
Intl655712.4 13.0 (0.6)
WW17515512.0 12.2 (0.2)
TOTAL CONSUMER HEALTH
US1,509 1,470 2.7 2.7 — 
Intl2,109 2,097 0.5 1.5 (1.0)
WW$3,618 3,567 1.4 %2.0 %(0.6)%
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5)
IMMUNOLOGY
US$2,8452,51713.0 %13.0 %— %
Intl1,2611,00525.4 21.1 4.3 
WW4,1053,52216.6 15.3 1.3 
     REMICADE
     US656755(13.1)(13.1)— 
     US Exports (6)
2568(62.4)(62.4)— 
     Intl2202123.3 2.7 0.6 
     WW9011,035(12.9)(13.1)0.2 
     SIMPONI / SIMPONI ARIA
     US3153024.4 4.4 — 
     Intl26121322.9 18.8 4.1 
     WW57651512.1 10.4 1.7 
     STELARA
     US1,5721,19431.6 31.6 — 
     Intl67250632.7 27.2 5.5 
     WW2,2441,70031.9 30.3 1.6 
     TREMFYA
     US276 199 39.1 39.1 — 
     Intl105 71 48.1 40.0 8.1 
     WW382 270 41.5 39.3 2.2 
     OTHER IMMUNOLOGY
     US— — — — — 
     Intl22(19.7)(14.5)(5.2)
     WW22(19.7)(14.5)(5.2)
INFECTIOUS DISEASES
US4704357.9 7.9 — 
Intl4424302.8 (2.6)5.4 
WW9128665.4 2.7 2.7 
     EDURANT / rilpivirine
     US11 14 (17.9)(17.9)— 
     Intl236 209 13.4 6.2 7.2 
     WW248 222 11.4 4.7 6.7 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US43339011.1 11.1 — 
     Intl136155(12.4)(17.1)4.7 
     WW5695444.4 3.1 1.3 
     OTHER INFECTIOUS DISEASES
     US2532(20.4)(20.4)— 
     Intl71675.2 3.3 1.9 
     WW9699(3.0)(4.3)1.3 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
NEUROSCIENCE
US$8067477.9 %7.9 %— %
Intl8928199.0 6.2 2.8
WW1,6981,5668.5 7.0 1.5
     CONCERTA / methylphenidate
     US3337(9.7)(9.7)—
     Intl1201154.2 1.4 2.8
     WW1531520.9 (1.2)2.1
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US6105648.1 8.1 —
     Intl355308 15.7 10.8 4.9
     WW96587110.8 9.0 1.8
     RISPERDAL CONSTA
     US7677(2.5)(2.5)—
     Intl928211.0 7.7 3.3
     WW1671604.4 2.7 1.7
     OTHER NEUROSCIENCE
     US887027.4 27.4 —
     Intl3263143.7 3.1 0.6
     WW4143838.0 7.5 0.5
ONCOLOGY
US1,4691,15327.4 27.4 —
Intl1,965 1,563 25.7 20.9 4.8
WW3,4342,71626.4 23.7 2.7
     DARZALEX
     US692 444 55.6 55.6 —
     Intl561 385 45.4 41.3 4.1
     WW1,253 830 50.9 49.0 1.9
     ERLEADA
     US176 103 70.8 70.8 —
     Intl64 13 ***
     WW241 116 ***
     IMBRUVICA
     US492 392 25.8 25.8 —
     Intl625 483 29.3 24.8 4.5
     WW1,117 875 27.8 25.3 2.5
     VELCADE
     US— — ———
     Intl97115(15.2)(18.5)3.3
     WW97115(15.2)(18.5)3.3
     ZYTIGA / abiraterone acetate
     US89194 (54.3)(54.3)—
     Intl53348310.2 4.3 5.9
     WW622677(8.3)(12.5)4.2
     OTHER ONCOLOGY
     US20 19 2.6 2.6 —
     Intl86841.5 (2.1)3.6
     WW1051041.7 (1.2)2.9
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
PULMONARY HYPERTENSION
US$592 388 52.5 %52.5 %— %
Intl273 235 16.8 12.5 4.3 
WW865 623 39.0 37.4 1.6 
     OPSUMIT
     US279 185 52.1 52.1 — 
     Intl173 143 21.2 16.9 4.3 
     WW452 326 38.6 36.7 1.9 
     UPTRAVI
     US263 178 48.2 48.2 — 
     Intl38 30 25.5 20.1 5.4 
     WW301 208 44.9 44.1 0.8 
     OTHER PULMONARY HYPERTENSION
     US49 26 84.9 84.9 — 
     Intl63 62 2.4 (1.2)3.6 
     WW112 88 26.6 24.1 2.5 
CARDIOVASCULAR / METABOLISM / OTHER
US935 930 0.6 0.6 — 
Intl317 327 (2.6)(5.4)2.8 
WW1,253 1,256 (0.2)(1.0)0.8 
     XARELTO
     US629 609 3.1 3.1 — 
     Intl— — — — — 
     WW629 609 3.1 3.1 — 
     INVOKANA / INVOKAMET
     US159 125 27.7 27.7 — 
     Intl58 52 11.5 8.9 2.6 
     WW217 177 22.9 22.1 0.8 
     PROCRIT / EPREX
     US62 118 (46.9)(46.9)— 
     Intl66 65 2.0 (1.1)3.1 
     WW129 183 (29.5)(30.6)1.1 
     OTHER
     US85 78 9.4 9.4 — 
     Intl194 209 (7.6)(10.3)2.7 
     WW278 286 (3.0)(5.0)2.0 
TOTAL PHARMACEUTICAL
US7,116 6,169 15.3 15.3 — 
Intl5,152 4,379 17.7 13.5 4.2 
WW$12,268 10,548 16.3 14.6 1.7 %
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5)
INTERVENTIONAL SOLUTIONS
US$433 377 14.8 %14.8 %— %
Intl460 39815.7 10.8 4.9 
WW893 77415.3 12.8 2.5 
ORTHOPAEDICS
US1,352 1,369 (1.3)(1.3)— 
Intl839 904 (7.3)(11.3)4.0 
WW2,191 2,273 (3.7)(5.3)1.6 
     HIPS
     US229 230 (0.7)(0.7)— 
     Intl143 147 (2.2)(5.8)3.6 
     WW372 377 (1.3)(2.7)1.4 
     KNEES
     US216 239 (9.5)(9.5)— 
     Intl129 156 (17.2)(20.6)3.4 
     WW345 395 (12.5)(13.9)1.4 
     TRAUMA
     US454 413 10.0 10.0 — 
     Intl268 273 (2.0)(6.2)4.2 
     WW722 686 5.2 3.6 1.6 
     SPINE, SPORTS & OTHER (7)
     US453 488 (7.1)(7.1)— 
     Intl299 329 (9.2)(13.6)4.4 
     WW752 817 (7.9)(9.7)1.8 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued)
SURGERY
US$1,002 961 4.3 %4.3 %— %
Intl1,427 1,481 (3.7)(5.9)2.2 
WW2,429 2,442 (0.5)(1.9)1.4 
     ADVANCED
     US456 428 6.5 6.5 — 
     Intl660 647 2.1 (0.9)3.0 
     WW1,116 1,076 3.8 2.0 1.8 
     GENERAL
     US546 534 2.5 2.5 — 
     Intl767 834 (8.1)(9.8)1.7 
     WW1,312 1,366 (4.0)(5.0)1.0 
VISION
US397 428 (7.3)(7.3)— 
Intl679 713 (4.7)(6.2)1.5 
WW1,076 1,141 (5.7)(6.6)0.9 
     CONTACT LENSES / OTHER
     US289 311 (7.4)(7.4)— 
     Intl507 522 (2.7)(4.1)1.4 
     WW796 833 (4.4)(5.3)0.9 
     SURGICAL
     US108 117 (7.1)(7.1)— 
     Intl172 191 (10.3)(12.0)1.7 
     WW280 309 (9.1)(10.1)1.0 
TOTAL MEDICAL DEVICES
US3,184 3,135 1.5 1.5 — 
Intl3,405 3,497 (2.6)(5.5)2.9 
WW$6,589 6,632 (0.7)%(2.2)%1.5 %
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20202019Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$2,460 2,010 22.4 %22.4 %— %
Intl2,364 2,434 (2.9)(1.2)(1.7)
WW4,824 4,444 8.5 9.4 (0.9)
SKIN HEALTH / BEAUTY (4)
US2,350 2,392 (1.7)(1.7)—
Intl2,100 2,201 (4.6)(2.3)(2.3)
WW4,450 4,593 (3.1)(2.0)(1.1)
ORAL CARE
US683 621 9.9 9.9 —
Intl958 906 5.7 9.6 (3.9)
WW1,641 1,528 7.4 9.7 (2.3)
BABY CARE
US376 362 3.7 3.7 —
Intl1,141 1,313 (13.1)(7.3)(5.8)
WW1,517 1,675 (9.4)(4.9)(4.5)
WOMEN'S HEALTH
US13 12 8.2 8.2 —
Intl888 974 (8.8)(2.9)(5.9)
WW901 986 (8.6)(2.7)(5.9)
WOUND CARE / OTHER
US480 441 8.9 8.9 —
Intl240 230 4.1 7.3 (3.2)
WW720 671 7.2 8.3 (1.1)
TOTAL CONSUMER HEALTH
US6,362 5,839 9.0 9.0 —
Intl7,691 8,059 (4.6)(1.3)(3.3)
WW$14,053 13,898 1.1 %3.0 %(1.9)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5)
IMMUNOLOGY
US$10,175 9,641 5.5 %5.5 %— %
Intl4,880 4,309 13.2 14.0 (0.8)
WW15,055 13,950 7.9 8.2 (0.3)
     REMICADE
     US2,508 3,079 (18.5)(18.5)—
     US Exports (6)
346 294 18.0 18.0 —
     Intl893 1,007 (11.4)(8.6)(2.8)
     WW3,747 4,380 (14.4)(13.8)(0.6)
     SIMPONI / SIMPONI ARIA
     US1,155 1,159 (0.3)(0.3)—
     Intl1,088 1,029 5.8 7.0 (1.2)
     WW2,243 2,188 2.6 3.1 (0.5)
     STELARA
     US5,240 4,346 20.6 20.6 —
     Intl2,467 2,015 22.4 22.2 0.2
     WW7,707 6,361 21.1 21.1 0.0
     TREMFYA
     US926 764 21.3 21.3 —
     Intl421 248 69.9 67.9 2.0
     WW1,347 1,012 33.2 32.7 0.5
     OTHER IMMUNOLOGY
     US— — ———
     Intl11 10 6.4 12.8 (6.4)
     WW11 10 6.4 12.8 (6.4)
INFECTIOUS DISEASES
US1,735 1,597 8.6 8.6 —
Intl1,839 1,815 1.3 2.2 (0.9)
WW3,574 3,413 4.7 5.2 (0.5)
     EDURANT / rilpivirine
     US44 50 (11.2)(11.2)—
     Intl920 812 13.3 11.9 1.4
     WW964 861 11.9 10.5 1.4
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US1,587 1,422 11.6 11.6 —
     Intl597 689 (13.4)(10.7)(2.7)
     WW2,184 2,110 3.5 4.4 (0.9)
     OTHER INFECTIOUS DISEASES
     US104 126 (17.6)(17.6)—
     Intl323 315 2.6 5.6 (3.0)
     WW427 441 (3.2)(1.0)(2.2)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
NEUROSCIENCE
US$3,091 2,919 5.9 %5.9 %— %
Intl3,457 3,409 1.4 2.2 (0.8)
WW6,548 6,328 3.5 3.9 (0.4)
     CONCERTA / methylphenidate
     US183 233 (21.4)(21.4)—
     Intl439 463 (5.1)(4.5)(0.6)
     WW622 696 (10.6)(10.2)(0.4)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US2,314 2,107 9.8 9.8 —
     Intl1,339 1,224 9.4 9.1 0.3
     WW3,653 3,330 9.7 9.6 0.1
     RISPERDAL CONSTA
     US296 314 (5.9)(5.9)—
     Intl346 374 (7.5)(6.9)(0.6)
     WW642 688 (6.8)(6.4)(0.4)
     OTHER NEUROSCIENCE
     US298 266 12.4 12.4 —
     Intl1,334 1,349 (1.1)0.7 (1.8)
     WW1,632 1,614 1.1 2.6 (1.5)
ONCOLOGY
US5,092 4,299 18.5 18.5 —
Intl7,275 6,393 13.8 14.0 (0.2)
WW12,367 10,692 15.7 15.8 (0.1)
     DARZALEX
     US2,232 1,567 42.4 42.4 —
     Intl1,958 1,430 36.9 38.0 (1.1)
     WW4,190 2,998 39.8 40.3 (0.5)
     ERLEADA
     US583 297 96.1 96.1 —
     Intl176 35 ***
     WW760 332 ***
     IMBRUVICA
     US1,821 1,555 17.1 17.1 —
     Intl2,307 1,856 24.3 25.1 (0.8)
     WW4,128 3,411 21.0 21.5 (0.5)
     VELCADE
     US— — ———
     Intl408 751 (45.7)(45.8)0.1
     WW408 751 (45.7)(45.8)0.1
     ZYTIGA / abiraterone acetate
     US373 810 (54.0)(54.0)—
     Intl2,097 1,985 5.6 4.7 0.9
     WW2,470 2,795 (11.6)(12.3)0.7
     OTHER ONCOLOGY
     US83 70 19.2 19.2 —
     Intl330 336 (1.9)(1.4)(0.5)
     WW413 407 1.7 2.2 (0.5)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
PULMONARY HYPERTENSION
US$2,133 1,684 26.6 %26.6 %— %
Intl1,015 939 8.2 8.0 0.2
WW3,148 2,623 20.0 20.0 0.0
     OPSUMIT
     US1,008 766 31.7 31.7 —
     Intl631 562 12.3 12.3 0.0
     WW1,639 1,327 23.5 23.5 0.0
     UPTRAVI
     US955 714 33.8 33.8 —
     Intl138 105 30.9 30.5 0.4
     WW1,093 819 33.5 33.4 0.1
     OTHER PULMONARY HYPERTENSION
     US169 205 (17.6)(17.6)—
     Intl247 272 (9.2)(9.4)0.2
     WW416 476 (12.8)(12.9)0.1
CARDIOVASCULAR / METABOLISM / OTHER
US3,509 3,734 (6.0)(6.0)—
Intl1,369 1,458 (6.1)(4.8)(1.3)
WW4,878 5,192 (6.0)(5.7)(0.3)
     XARELTO
     US2,345 2,313 1.4 1.4 —
     Intl— — — — —
     WW2,345 2,313 1.4 1.4 —
     INVOKANA / INVOKAMET
     US564 536 5.2 5.2 —
     Intl231 199 16.3 17.6 (1.3)
     WW795 735 8.2 8.6 (0.4)
     PROCRIT / EPREX
    US277 505 (45.1)(45.1)—
     Intl274 285 (3.8)(3.6)(0.2)
     WW552 790 (30.2)(30.1)(0.1)
     OTHER
     US323 380 (15.1)(15.1)—
     Intl864 974 (11.3)(9.7)(1.6)
     WW1,186 1,353 (12.4)(11.2)(1.2)
TOTAL PHARMACEUTICAL
US25,735 23,874 7.8 7.8 —
Intl19,837 18,324 8.3 8.8 (0.5)
WW$45,572 42,198 8.0 %8.2 %(0.2)%
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5)
INTERVENTIONAL SOLUTIONS
US$1,452 1,443 0.6 %0.6 %— %
Intl1,594 1,554 2.6 2.0 0.6 
WW3,046 2,997 1.6 1.3 0.3 
ORTHOPAEDICS
US4,779 5,319 (10.2)(10.2)—
Intl2,984 3,520 (15.2)(15.4)0.2 
WW7,763 8,839 (12.2)(12.3)0.1 
     HIPS
     US793 863 (8.2)(8.2)—
     Intl487 575 (15.3)(15.1)(0.2)
     WW1,280 1,438 (11.0)(11.0)0.0 
     KNEES
     US743 889 (16.4)(16.4)—
     Intl427 591 (27.8)(28.0)0.2 
     WW1,170 1,480 (21.0)(21.1)0.1 
     TRAUMA
     US1,648 1,652 (0.2)(0.2)—
     Intl966 1,068 (9.6)(9.7)0.1 
     WW2,614 2,720 (3.9)(3.9)0.0 
     SPINE, SPORTS & OTHER (7)
     US1,595 1,915 (16.7)(16.7)—
     Intl1,104 1,286 (14.1)(14.6)0.5 
     WW2,699 3,201 (15.7)(15.9)0.2 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued)
SURGERY
US$3,249 3,828 (15.1)%(15.1)%— %
Intl4,983 5,673 (12.2)(11.2)(1.0)
WW8,232 9,501 (13.4)(12.8)(0.6)
     ADVANCED
     US1,535 1,637 (6.2)(6.2)—
     Intl2,304 2,458 (6.2)(5.6)(0.6)
     WW3,839 4,095 (6.2)(5.8)(0.4)
     GENERAL
     US1,714 2,192 (21.8)(21.8)—
     Intl2,679 3,215 (16.7)(15.5)(1.2)
     WW4,392 5,406 (18.8)(18.0)(0.8)
VISION
US1,557 1,794 (13.2)(13.2)—
Intl2,362 2,830 (16.5)(16.2)(0.3)
WW3,919 4,624 (15.2)(15.1)(0.1)
     CONTACT LENSES / OTHER
     US1,213 1,304 (7.0)(7.0)—
     Intl1,781 2,088 (14.7)(14.4)(0.3)
     WW2,994 3,392 (11.7)(11.5)(0.2)
     SURGICAL
     US344 490 (29.7)(29.7)—
     Intl581 742 (21.7)(21.5)(0.2)
     WW925 1,232 (24.9)(24.7)(0.2)
TOTAL MEDICAL DEVICES
US11,036 12,384 (10.9)(10.9)—
Intl11,923 13,579 (12.2)(11.8)(0.4)
WW$22,959 25,963 (11.6)%(11.4)%(0.2)%
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
(6) Reported as U.S. sales
(7) Previously referred to as Spine & Other